PDCD1 and head and neck squamous cell carcinoma: Previous trials demonstrated that patients with recurrent or metastatic HNSCC treated with PD-1 inhibitors tolerated the drugs well, had ORR of up to 18%, and had long-lasting responses not usually observed with chemotherapy [50, 51].